𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Disease-modifying approaches to Alzheimer’s disease: Challenges and opportunities—Lessons from donepezil therapy

✍ Scribed by Marwan N. Sabbagh; Sharon Richardson; Norman Relkin

Book ID
118463533
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
216 KB
Volume
4
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Switching cholinesterase inhibitor thera
Switching cholinesterase inhibitor therapy in Alzheimer's disease—donepezil to rivastigmine, is it worth it?
✍ Roger Bullock; Claire Connolly 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 1 views

Switching from donepezil to rivastigmine was bene®cial in cognitive and global terms in 55.0% of the patients with Alzheimer's disease studied. \* Side-effects on donepezil and rivastigmine were independent of one another. \* It may be possible to extend the positive effects that cholinesterase inhi

From cyclooxygenase activities to Alzhei
From cyclooxygenase activities to Alzheimer's disease neuropathology:experimental approaches and therapeutic interventions
✍ Giulio Maria Pasinetti 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

## Abstract Several prospective and retrospective epidemiological studies have demonstrated a protective effect for antiinflammatory drugs in Alzheimer's disease (AD). However, despite this evidence therapeutic studies investigating nonsteroidal antiinflammatory drugs (NSAIDs), including cyclooxyge